289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

✍ Scribed by J.L. Raoul; J.L. van Laethem; E. Mitry; C. Brezault; F. Husseini; L. Cals; M. Peeters; J.C. Vedovato; M. Mueser; P. Rougier

• Book ID: 118620464
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 170 KB
• Volume: 1
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(03)90322-3